← InsureGuardAI blog

The reinsurance deal died on one line of the sanctions questionnaire

The Underwriting Director treated sanctions screening the way most of us were trained to: an internal hygiene task. Run the name at bind, file the clear, move on. It was a compliance checkbox owned somewhere down the org chart, not something that ever touched the commercial side of a deal.

Then a treaty placement reached the reinsurer's due diligence stage, and one line on their questionnaire asked for the screening methodology in writing. Coverage, cadence, UBO approach, audit evidence. The team had an onboarding OFAC check and nothing behind it. The risk was fine. The control could not be evidenced, and on that placement, those are the same thing.

Why reinsurers and banking partners now ask for your screening methodology

The reinsurer is not screening your cedents. They are screening you, because under a quota share or excess-of-loss treaty they inherit your exposure, and a designated party in your book becomes their problem on a balance sheet they answer for. So they ask the same question a correspondent bank asks before opening a nostro account: show me how you do this, not that you do it.

This is not a vibe shift. On 13 November 2024, OFAC issued its first substantive update to insurer-specific guidance since 2015, and several of those FAQs had not been touched in over twenty years. The direction was explicit: insurers are expected to run sanctions controls comparable in effectiveness to a bank's, with adequate diligence on counterparties, administrators, and service providers. Once the regulator writes that down, counterparties start diligencing to it.

The questions that lose deals: coverage, cadence, UBO, and audit evidence

A bind-only screen answers none of the four things a serious counterparty asks. It is worth being precise about what they actually want, because vague reassurance reads as a gap:

"We use a sanctions tool" is not an answer to any of those. The Underwriting Director found out which question was load-bearing only after the deal was already cooling.

Converging bank-grade expectations onto insurers post-2022

Since the wave of designations that followed Russia's 2022 invasion of Ukraine, the gap between how banks and insurers are expected to manage sanctions risk has closed fast. Banks have re-screened portfolios against list deltas for years; an insurer that only screens at onboarding is now visibly behind a standard the market already treats as table stakes. Counterparties have noticed, and their questionnaires reflect it.

The practical consequence is that screening migrated out of compliance and into commercial. A program you can document becomes a thing you can put in front of a reinsurer's analyst. A program you can only describe becomes a reason to re-price, slow-walk, or decline the placement. The control did not change function. Its audience did.

Turning a documented program into a procurement advantage

The flip side of losing a deal on this is winning one. The insurers clearing these questionnaires cleanly are not the ones with the most expensive tooling; they are the ones who can export, on demand, a record showing who was screened, when, against which list version, with which matches cleared and why. That artifact answers the questionnaire before the analyst finishes reading their template, and it shortens the diligence cycle for every future treaty.

InsureGuardAI is built so the evidence is a byproduct of doing the screening, not a separate scramble when a counterparty asks. Continuous re-screening against list changes, UBO resolution through the ownership chain, and a case file that retains the raw match response all live in one workspace, exportable as the methodology pack a reinsurer or bank will want to see. You can see how it works and stop treating your sanctions program as a cost when it has quietly become a thing you sell.